New perspectives on monoclonal proteins
Section 01 — The clinical challenge
Why M-protein glycosylation is a critical yet hidden risk factor
The monoclonal protein (M-protein) is a key biomarker used in the diagnosis and monitoring of patients with monoclonal gammopathies.1 Although traditionally measured using electrophoretic techniques, more advanced technologies such as MALDI-TOF mass spectrometry are now providing new opportunities for analysis and characterization.2 This case study examines how MALDI-TOF mass spectrometry enables detection of M-protein glycosylation, specifically N-linked glycosylation on immunoglobulin light chains, a modification that electrophoretic methods cannot reliably characterize.
Glycosylated monoclonal light chains are a potent risk factor for progression to malignant plasma cell disorders, yet conventional electrophoretic methods cannot reliably identify them.
N-linked glycosylation is a post-translational modification involving the attachment of glycans to the immunoglobulin light chain, increasing its molecular mass and altering its diagnostic profile.3 When detected by the EXENT GAM assay, these glycosylated M-proteins are referred to as 'mass shifted light chains' (MSLs).
To illustrate this, two patient serum samples were analyzed using the EXENT GAM assay to demonstrate the contrast between non-glycosylated and glycosylated M-proteins.
AT A GLANCE
Clinical challenge: Identifying glycosylated monoclonal light chains
Technology: EXENTTM GAM assay with MALDI-ToF mass spectrometry
Key capability: Automatic detection and flagging of mass shifted light chains
Section 02 — The patient
Comparing non-glycosylated and glycosylated monoclonal light chains
The first sample demonstrates a non-glycosylated light chain characterized by a single sharp peak at a mass-to-charge ratio of 11,640 in both the IgG and kappa spectra (Figure 1A). The second sample presented a markedly different pattern, with broad and irregular clusters of peaks in the extended mass window, reflecting the presence of different glycoforms of the M-protein (Figure 1B).
Section 03 — The breakthrough
How the EXENT GAM assay reveals M-protein glycosylation
The EXENT GAM assay detected and quantified M-proteins in both samples. The non-glycosylated M-protein was quantified at 9.3 g/L (Figure 1A) and the glycosylated M-protein was quantified at 39.5 g/L (Figure 1B).
Download the full case study to explore the EXENT GAM assay's approach to M-protein characterization, including annotated spectra for both non-glycosylated and glycosylated light chains.
Figures referenced on this page are available in the full case study PDF.
PDF · 2 pages
New perspectives on monoclonal proteins
Includes Figures 1A–2B and full references
EXENT GAM ASSAY FINDINGS
9.3g/L and 39.5g/L
Non-glycosylated and glycosylated M-proteins quantified
The EXENT GAM assay quantified M-proteins in both samples, demonstrating its ability to characterise both non-glycosylated and glycosylated light chains.
Section 04 — Hear from the experts
Expert insights on mass spectrometry and monoclonal protein characterization
Podcast 4
Podcast episode
Listen to our podcast episode where our scientists discuss the value of detecting glycosylated M-proteins and what this means for patients.
"Being able to provide this additional characterization of the patient's unique M-protein may potentially help guide clinical decisions and lead to better patient outcomes."
—Dr. Jane Birtwistle, Manager in Medical and Scientific Affairs, Binding Site, Part of Thermo Fisher Scientific
Section 05 — Broader clinical validation
Glycosylated light chains as a predictor of MGUS progression
In a retrospective study, Dispenzieri et al. 2020 used mass spectrometry to evaluate the association between detection of glycosylated light chains at MGUS diagnosis and subsequent disease progression to AL Amyloidosis and other malignant plasma cell disorders.4 Using serum samples from the Olmsted MGUS screening cohort, the study showed that 20 years after diagnosis, 67% of patients with glycosylated light chains progressed to malignant disease, compared to only 13% of patients without glycosylated light chains.4
The authors concluded: "The recognition that glycosylated monoclonal light chains pose a risk for progression could lead to earlier diagnoses of AL and other PCDs (plasma cell disorders), which could translate into reduced morbidity and mortality."4
67% of patients with glycosylated light chains progressed to malignancy, compared to 13% without.4
Section 06 — Implications
Key points for clinical practice
01
MALDI-TOF mass spectrometry can identify mass shifted immunoglobulin light chains due to the increased molecular mass and their characteristic clustered peak shape.
02
M-protein glycosylation has been shown to be a potent risk factor for progression to malignant plasma cell disorders.4
03
Automated flagging by the EXENT analyzer may simplify interpretation of complex spectra for laboratory scientists, reducing the need for specialist manual review.
04
Incorporating glycosylation status into MGUS risk stratification could support earlier identification of patients requiring closer monitoring or intervention.
Section 07 – Next Steps
Explore the EXENT system
Ready to bring enhanced M-protein detection to your laboratory?
Learn about the EXENT system
First-of-its-kind automated mass spectrometry.
Explore the EXENT GAM assay
Enhanced sensitivity for low-level M-proteins.
View all clinical case studies
Real-world results across disease groups.
Contact us about your lab's needs
Speak with a product specialist.
References
- Tate JR. Clin Biochem Rev 2019; 40:5-22.
- Milani P, et al. Am J Hematol 2017; 92:772-779.
- Kumar S, et al. Leukemia 2019; 33:254-257.
- Dispenzieri A, et al. Leukemia 2020; 34:2749-2753.
The EXENT system combines EXENT analyzer with the Immunoglobulin Isotypes (GAM) for the EXENT analyzer. EXENT GAM assay refers to Immunoglobulin Isotypes (GAM) for the EXENT analyzer